Steroids for AL Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Patient Education

Steroids for AL Amyloidosis

key information

source: Myeloma UK

year: 2017

summary/abstract:

Steroids are drugs which mimic certain hormones in the body that help to regulate and control the way the body develops and functions. There are several types of steroids. Those used in the treatment of AL amyloidosis are known as glucocorticoids.

 
Glucocorticoid steroids are known to be effective in killing abnormal plasma cells in the bone marrow without damaging normal bone marrow function. These steroids can also suppress the immune system, which can help to reduce pain caused by inflammation.
 
What Steroids are Available to Treat AL Amyloidosis?
Dexamethasone and prednisolone are the steroids most commonly used in treating AL amyloidosis. While they may be used on their own (as a monotherapy) steroids are most commonly used in combination with other AL amyloidosis treatments.
 
Steroid-containing treatment combinations include:
 
  • Melphalan and dexamethasone (Mel-Dex)
  • Melphalan and prednisolone (MP)
  • Cyclophosphamide, thalidomide and dexamethasone (CTD)
  • Cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD)
 
read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close